Price T Rowe Associates Inc Novo Cure LTD Transaction History
Price T Rowe Associates Inc
- $869 Billion
- Q3 2024
A detailed history of Price T Rowe Associates Inc transactions in Novo Cure LTD stock. As of the latest transaction made, Price T Rowe Associates Inc holds 2,322,196 shares of NVCR stock, worth $73.7 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,322,196
Previous 2,156,021
7.71%
Holding current value
$73.7 Million
Previous $36.9 Million
1.72%
% of portfolio
0.0%
Previous 0.0%
Shares
16 transactions
Others Institutions Holding NVCR
# of Institutions
263Shares Held
77MCall Options Held
1.17MPut Options Held
318K-
Black Rock Inc. New York, NY12.1MShares$385 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.8MShares$376 Million0.0% of portfolio
-
Capital International Investors Los Angeles, CA7.92MShares$252 Million0.02% of portfolio
-
Capital World Investors Los Angeles, CA4.31MShares$137 Million0.01% of portfolio
-
Nordwand Advisors, LLC Radnor, PA3.03MShares$96.2 Million12.67% of portfolio
About NovoCure Ltd
- Ticker NVCR
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Instruments & Supplies
- Shares Outstandng 104,950,000
- Market Cap $3.33B
- Description
- NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...